Published on 18th March 2014

Bioquell PLC  - provider of specialist bio-contamination control technologies to the international Healthcare, Life Sciences & Defence markets; and specialist testing services in the UK via its TRaC division, today announces its preliminary results for the year ended 31 December, 2013. -

Highlights

  • Group revenues up by 9% to £44.6 million (2012: £41.0 million) - Bio division up 8% to £27.8 million & TRaC up 11% to £16.8 million
  • Pre-tax profits including reconfiguration costs of £0.9 million were £3.1 million (2012: £4.0 million). Adjusting for reconfiguration costs, pre-tax profits were £4.0 million (2012: £4.0 million)
  • Basic earnings per share of 7.3p (2012: 9.6p)
  • Proposed dividend per share of 3.3p (2012: 3.06p), an increase of 8%
  • Net cash at the year end was £2.0 million (2012: £1.9 million)
  • New products in the Bio division generating encouraging activity levels: QUBE orders already from USA, India, Brazil, Japan as well as Europe - and increasing international interest in ICE-pod
  • Expanding opportunities in the Life Sciences and Healthcare sectors due to increased regulatory oversight and extreme antibiotic resistance
  • Our focus on consumables is beginning to result in increased levels of higher margin recurring revenues
  • TRaC is well positioned for further growth in the UK and overseas

Nigel Keen, Chairman of Bioquell PLC, said:

"Our Bio division is seeking to exploit a number of strong drivers for profitable growth in 2014.  These include the increasingly robust stance adopted by the regulators in the Life Sciences sector, the clear and increasing problems associated with antibiotic resistance in the Healthcare sector as well as an improved business model which should generate a greater proportion of recurring revenues from sales of high margin consumables and rental products. However, in this division the year has started somewhat more slowly than we had expected but enquiries for our new products, especially from overseas markets, are encouraging."

"TRaC has good momentum, excellent facilities, exposure to an international client base and an expanding range of high value services, many of which can be delivered without the need for substantial investment in additional capital equipment."

Downloads
  • Bioquell PLC announces its 2013 preliminary results
  • Bioquell 2013 Preliminary results & update on progress
distributed by